Palvella Therapeutics, Inc.
PVLAHealthcare|Biotechnology|US
$175.92
+19.07 (+12.16%)
DCF Value
$4.71
Tangible Book / Share
$13.62
Cash / Share
$16.29
About
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Stock Price
+123.7%(1Y)
1M
+33.9%
3M
+11.5%
6M
+45.0%
YTD
+68.1%
1Y
+119.1%
3Y
+934.8%
5Y
+934.8%
Pipeline Summary
9 total trials0
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
Completed: 5Recruiting: 2Active: 2
Active Trials (4)
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
NCT05643872Pachyonychia Congenita
Phase 3Recruiting
Enrollment: 45 participants
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842Cutaneous Venous Malformations
Phase 2Active
Enrollment: 15 participants
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480Microcystic Lymphatic Malformation
Phase 3Active
Enrollment: 51 participants
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
NCT07552077Angiokeratomas
Phase 2Recruiting
Enrollment: 15 participants
Key Facts
Market Cap$2.53B
Employees29 (+107% YoY)
CEOWesley H. Kaupinen
IPO DateJan 2, 2015
Beta-0.17
52-Week Range$72.22 – $176.94
Avg Volume224,461
ExchangeNASDAQ
Websitepalvellatx.com
Ownership
Float63.6%
Shares Outstanding14.4M
Recent Insider Trades
Goin KathleenOPTION EX.
Oct 21, 20262,148 shares @ $9.08
Goin KathleenSELL
Oct 21, 20262,043 shares @ $123.62
Goin KathleenOPTION EX.
Oct 21, 20262,165 shares @ $7.14
Goin KathleenSELL
Oct 21, 20261,663 shares @ $125.16
Goin KathleenOPTION EX.
Oct 21, 20262,165 shares @ $7.14
Peers
Recent News
Palvella Therapeutics, Inc. (PVLA) Q3 2026 Earnings Call Transcript
Nov 8, 2026 · seekingalpha.com
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
Nov 5, 2026 · marketbeat.com
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026 · globenewswire.com
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
Nov 3, 2026 · globenewswire.com
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
Oct 29, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:30 AM